医学
淋巴瘤
癌症
Bcl-2家族
白血病
癌症研究
癌细胞
肿瘤科
程序性细胞死亡
细胞凋亡
免疫学
内科学
生物
遗传学
作者
Matthew S. Davids,Anthony Letai
标识
DOI:10.1200/jco.2011.37.0981
摘要
The B-cell lymphoma/leukemia 2 (BCL-2) family of proteins has attracted the attention of cancer biologists since the cloning of BCL-2 more than 25 years ago. In the intervening decades, the way the BCL-2 family controls commitment to programmed cell death has been greatly elucidated. Several drugs directed at inhibiting BCL-2 and related antiapoptotic proteins have been tested clinically, with some showing considerable promise, particularly in lymphoid malignancies. A better understanding of the BCL-2 family has also provided insight into how conventional chemotherapy selectively kills cancer cells and why some cancers are more chemosensitive than others. Further exploitation of our understanding of the BCL-2 family promises to offer improved predictive biomarkers for oncologists and improved therapies for patients with cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI